The DEA recently published a final ruling on the classification of the steroids methasterone and prostanozol as anabolic steroids under Schedule III of the Controlled Substances Act. This was proposed in November of last year and has now been signed into action, coming into effect on the 29th August 2012.
The two steroids have been determined to be chemically and pharmacologically related to testosterone and are not estrogens, progestins, corticosteroids, or dehydroepiandrosterone according to the criteria that classifies anabolic steroids in the Controlled Substances Act.
As of the effective date of this Final Rule, the manufacture, import, export, distribution, or sale of prostanozol or methasterone, except by DEA registrants, is a violation of the CSA that may result in imprisonment and fines (see, e.g., 21 U.S.C. 841 and 960).
Possession of these two steroids, unless legally obtained, is also subject to criminal penalties pursuant to 21 U.S.C. 844
Any individual who purchases either of these substances directly from foreign companies and has them shipped to the United States will be considered to be importing even if the steroids are intended for personal use. Illegal importation of these substances will be a violation of the CSA that may result in imprisonment and fines pursuant to 21 U.S.C. 960.
Although the date of ruling was July 30th, the law comes into effect August 29th (30 days after the ruling). Anyone in possession of these drugs is urged to contact their local DEA office to arrange their disposal.
Persons who possess substances that become classified as anabolic steroids and who wish to dispose of them rather than becoming registered to handle them should contact their local DEA Diversion field office for assistance in disposing of these substances legally pursuant to 21 CFR 1307.21.
Methasterone is structurally similar to the injectable steroid masteron, but has the addition of a 17α-methyl group that greatly improves oral bioavailability. Commonly known as superdrol, it has been one of the most widely ‘cloned’ over-the-counter steroids since its introduction to the ‘dietary supplement’ market in 2005.
Some examples of methasterone clones include LGI SD-10, Primordial Performance Superdrone, Competitive Edge Labs M-drol, and Anabolic Xtreme Superdrol.
Prostanozol is structurally similar to the anabolic steroid stanozolol, though lacks the 17α-methyl group that confers good oral bioavailability on the latter compound. For this reason prostanozol is typically sold in the form of its THP-ether.
Some examples of Prostanozol clones include AX Prostanozol, Generic Labz Mega-Zol, Gaspari Nutrition Orastan-E, Competitive Edge Labs P-stanz, and Dynamic Formulas P-stane.
Comment: One commenter disagreed that anabolic steroids, and in particular those encountered in dietary supplements, should be placed in Schedule III of the CSA. He indicated that classifying these substances as Schedule III anabolic steroids would force the public to procure other, nonregulated and unsafe substitutes from illicit sources in the future, and that DEA should employ an alternate method of regulation.
DEA Response: DEA disagrees with this comment. The United States Food and Drug Administration has issued multiple warnings regarding dietary supplements, especially concerning contamination through novel synthetic steroids that do not qualify as dietary ingredients.
Superdrol is, in fact, already available on the black market from a few underground labs. Given the massive popularity of superdrol as an over-the-counter ‘dietary supplement’, an increase in the number of UGLs selling superdrol would seem probable. This has already been seen with the previously banned ‘phera’ (desoxymethyltestosterone) and ‘M1T’ (17α-methyl-1-testosterone).
It appears that the futility of this piecemeal approach to the regulation of designer steroids has finally been recognised, as a much wider-reaching bill (that seeks to restrict the sale and possession of all designer steroids, as well as altering the definition of an anabolic steroid) has recently been proposed. You can expect more on the proposed legislation (the Designer Anabolic Steroid Control Act 2012) in a future article.